Day One Biopharmaceuticals will host a conference call on February 25, 2025, to discuss Q4 and full-year 2024 results.
Quiver AI Summary
Day One Biopharmaceuticals has announced that it will conduct a live conference call and webcast on February 25, 2025, at 4:30 p.m. ET to present its financial results and discuss corporate developments for the fourth quarter and full year of 2024. Interested parties can access the live audio through the Day One Investors & Media page, with an archived version available for 30 days afterward. The company, based in Brisbane, California, focuses on developing targeted therapies for severe diseases in both children and adults. Day One aims to innovate in drug development to improve treatment options for patients, particularly in oncology, with a pipeline that includes products like tovorafenib (OJEMDA™). The company actively communicates updates and announcements through its investor relations channels online.
Potential Positives
- Day One Biopharmaceuticals is hosting a live conference call and webcast to discuss its financial results and corporate progress, indicating transparency and engagement with investors.
- The company is focused on developing targeted therapies for life-threatening diseases in both children and adults, highlighting its commitment to addressing critical healthcare needs.
- Day One’s pipeline includes promising product candidates, such as tovorafenib (OJEMDA™), which may provide new treatment options for patients, showcasing the company's potential for future growth.
- The establishment of a "search & development" strategy demonstrates an innovative approach to hastening the introduction of new therapies, which could enhance the company's reputation and market position.
Potential Negatives
- Failure to provide specific details about financial performance may lead to investor uncertainty regarding the company's stability and growth prospects.
- Highlighting the traditional drug development model's shortcomings could raise concerns about the effectiveness and efficiency of Day One's current strategies.
- Emphasis on the need for new therapies might indicate dissatisfaction with the existing pipeline, suggesting that the company's current offerings are insufficient or lacking progress.
FAQ
When is Day One Biopharmaceuticals' next conference call?
Day One Biopharmaceuticals' next conference call is scheduled for February 25, 2025, at 4:30 p.m. ET.
How can I access the live webcast of the conference call?
The live audio of the webcast can be accessed on the Day One Investors & Media page.
Will a recording of the conference call be available later?
Yes, an archived version of the webcast will be available for replay for 30 days following the event.
What is the focus of Day One Biopharmaceuticals?
Day One Biopharmaceuticals focuses on developing targeted therapies for life-threatening diseases in both children and adults.
What are some key programs in Day One's pipeline?
Key programs in Day One's pipeline include tovorafenib (OJEMDA™), DAY301, and a VRK1 inhibitor program.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$DAWN Insider Trading Activity
$DAWN insiders have traded $DAWN stock on the open market 14 times in the past 6 months. Of those trades, 0 have been purchases and 14 have been sales.
Here’s a breakdown of recent trading of $DAWN stock by insiders over the last 6 months:
- SAMUEL C. BLACKMAN (HEAD OF R&D) has made 0 purchases and 8 sales selling 104,438 shares for an estimated $1,530,921.
- JEREMY BENDER (CHIEF EXECUTIVE OFFICER) has made 0 purchases and 2 sales selling 21,235 shares for an estimated $288,944.
- ADAM DUBOW (GENERAL COUNSEL) has made 0 purchases and 2 sales selling 6,367 shares for an estimated $86,635.
- CHARLES N II YORK (COO, CFO AND SECRETARY) has made 0 purchases and 2 sales selling 5,235 shares for an estimated $71,232.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$DAWN Hedge Fund Activity
We have seen 98 institutional investors add shares of $DAWN stock to their portfolio, and 63 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 4,750,936 shares (+178.5%) to their portfolio in Q3 2024, for an estimated $66,180,538
- FAIRMOUNT FUNDS MANAGEMENT LLC added 3,103,448 shares (+inf%) to their portfolio in Q3 2024, for an estimated $43,231,030
- BRAIDWELL LP added 1,837,949 shares (+60.5%) to their portfolio in Q3 2024, for an estimated $25,602,629
- BLACKROCK, INC. added 1,446,675 shares (+30.7%) to their portfolio in Q4 2024, for an estimated $18,329,372
- VANGUARD GROUP INC added 1,263,938 shares (+27.3%) to their portfolio in Q3 2024, for an estimated $17,606,656
- VESTAL POINT CAPITAL, LP added 1,250,000 shares (+100.0%) to their portfolio in Q3 2024, for an estimated $17,412,500
- FIRST TURN MANAGEMENT, LLC added 947,878 shares (+inf%) to their portfolio in Q3 2024, for an estimated $13,203,940
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
BRISBANE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, February 25, 2025 at 4:30 p.m. ET to report financial results and discuss corporate progress for the fourth quarter and full-year 2024.
Live audio of the webcast will be accessible on the Day One Investors & Media page. An archived version of the webcast will be available for replay on the Events & Presentations section of the Day One Investors & Media page for 30 days following the event.
About Day One Biopharmaceuticals
Day One Biopharmaceuticals is a commercial-stage company focused on advancing first- or best-in-class medicines for childhood and adult diseases with equal intensity. We were founded to address the lack of new therapies resulting from the traditional drug development model, which has left children with cancer and their families waiting too long for new treatments.
At Day One, we aim to identify and develop breakthrough medicines with the goal of improving the outcomes and life trajectories of patients of any age facing serious diseases — starting from Day One. Our “search & development” strategy enables us to find, acquire, and develop potential best-or first-in-class programs with the goal of introducing new medicines that will make a real difference in the treatment of children and adults.
Day One’s pipeline includes tovorafenib (OJEMDA™), DAY301 and a VRK1 inhibitor program. The Company is based in Brisbane, California and can be found online at www.dayonebio.com , LinkedIn or X .
Day One uses its Investor Relations website (ir.dayonebio.com), its X handle (x.com/DayOneBio), and LinkedIn Home Page (linkedin.com/company/dayonebio) as a means of disseminating or providing notification of, among other things, news or announcements regarding its business or financial performance, investor events, press releases, and earnings releases, and as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.
DAY ONE MEDIA
Laura Cooper, Head of Communications
[email protected]
DAY ONE INVESTORS
LifeSci Advisors, PJ Kelleher
[email protected]
